{"title":"Clinical Impact of Osteolytic Bone Lesions in POEMS Syndrome: A Single-Center Experience of 114 Patients","authors":"Tatsuzo Mishina, Chikako Ohwada, Tomoki Suichi, Shinichiro Matsui, Arata Ishii, Koji Takaishi, Nagisa Oshima-Hasegawa, Shokichi Tsukamoto, Yusuke Takeda, Sonoko Misawa, Naoya Mimura, Satoshi Kuwabara, Chiaki Nakaseko, Emiko Sakaida","doi":"10.1002/hon.70037","DOIUrl":"10.1002/hon.70037","url":null,"abstract":"<div>\u0000 \u0000 <p>POEMS syndrome is a multisystemic disease associated with monoclonal plasma cell disorders. Although the presence of bone lesions is included in the diagnostic criteria, their precise manifestations remain unknown. Here, we retrospectively analyzed the bone lesions in patients with POEMS syndrome and evaluated their clinical features. Clinical data and bone lesion information by computed tomography (CT) imaging were obtained from the 114 patients with POEMS syndrome. Regardless of the presence of sclerotic bone lesions, patients were divided into two groups according to the presence (lytic group: <i>n</i> = 17, 14.9%) or absence (non-lytic group: <i>n</i> = 97, 85.1%) of osteolytic lesions. In the lytic group, several patients were histologically diagnosed with plasmacytoma. In the evaluation by CT imaging, osteolytic lesions had a higher response rate than sclerotic lesions (75.0% vs. 42.2%, <i>p</i> = 0.079). Nevertheless, patients in lytic group showed earlier clinical progression than patients in non-lytic group (2-year progression-free survival, 66.7% vs. 90.2%, <i>p</i> = 0.069). The presence of innumerable bone lesions was an independent poor prognostic factor in multivariate analysis, regardless of the presence of osteolytic lesions (hazard ratio, 3.4; 95% confidence interval 1.1–10.9; <i>p</i> = 0.040). Osteolytic and innumerable bone lesions are potential prognostic factors. Further studies involving histopathological evaluations of bone lesions are warranted.</p>\u0000 </div>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pinelopi Vryttia, Anthi Bouchla, Christina Apostolopoulou, Artemis Zorba, Thomas Thomopoulos, Ioulia Markaki, Periklis G. Foukas, Vasiliki Pappa, Sotirios G. Papageorgiou
{"title":"The Role of 24-Month Progression-Free Survival (PFS24) in the Long-Term Evaluation of Patients With Diffuse Large B Cell Lymphoma (DLBCL): A Real-World Single Center Study","authors":"Pinelopi Vryttia, Anthi Bouchla, Christina Apostolopoulou, Artemis Zorba, Thomas Thomopoulos, Ioulia Markaki, Periklis G. Foukas, Vasiliki Pappa, Sotirios G. Papageorgiou","doi":"10.1002/hon.70034","DOIUrl":"10.1002/hon.70034","url":null,"abstract":"","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142947672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Minna Harmanen, Mika Hujo, Reijo Sund, Marc Sorigue, Madiha Khan, Roosa Prusila, Tuula Klaavuniemi, Esa Kari, Esa Jantunen, Kaisa Sunela, Aino Rajamäki, Erika Alanne, Hanne Kuitunen, Juan-Manuel Sancho, Arja Jukkola, Aino Rönkä, Outi Kuittinen
{"title":"Lifetime Treatment Trajectories of Mantle Cell Lymphoma: Simulation Based Analysis of 20 Years of Real-World Data","authors":"Minna Harmanen, Mika Hujo, Reijo Sund, Marc Sorigue, Madiha Khan, Roosa Prusila, Tuula Klaavuniemi, Esa Kari, Esa Jantunen, Kaisa Sunela, Aino Rajamäki, Erika Alanne, Hanne Kuitunen, Juan-Manuel Sancho, Arja Jukkola, Aino Rönkä, Outi Kuittinen","doi":"10.1002/hon.70024","DOIUrl":"10.1002/hon.70024","url":null,"abstract":"<div>\u0000 \u0000 <p>Mantle cell lymphoma is a rare type of B-cell lymphoma, which is considered incurable yet treatable. In recent years, the treatment options of mantle cell lymphoma have multiplied, and the focus of treatment is expected to shift from traditional chemoimmunotherapy toward precision medicine. However, this development is hindered by the high costs of targeted therapies. To provide a baseline for future assessment of costs and benefits of new and emerging MCL treatments, we established a predictive simulated model of lifetime treatment trajectories based on a retrospective cohort of chemoimmunotherapy era patients diagnosed and treated between the year 2000 and 2020.</p>\u0000 </div>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142947668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Childhood ALL and Asparaginase Intensification: Are We at the Brink?","authors":"Shyam Srinivasan","doi":"10.1002/hon.70032","DOIUrl":"10.1002/hon.70032","url":null,"abstract":"","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142921447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
H. Moatti, P. Brice, M-C. Laroque, R. Di Blasi, J. Wencel, T. Delory, I. Madelaine-Chambrin, C. Schmidt-Hieber, O. Ravdan, C. Thieblemont, L. Renaud
{"title":"One-Day Brentuximab–Bendamustine (120 mg/m2) Every 21 Days is a Feasible, Safe and Effective Treatment for Relapsed/Refractory Hodgkin Lymphoma","authors":"H. Moatti, P. Brice, M-C. Laroque, R. Di Blasi, J. Wencel, T. Delory, I. Madelaine-Chambrin, C. Schmidt-Hieber, O. Ravdan, C. Thieblemont, L. Renaud","doi":"10.1002/hon.70031","DOIUrl":"10.1002/hon.70031","url":null,"abstract":"<div>\u0000 \u0000 <p>Brentuximab vedotin (BV)-bendamustine (90 or 120 mg/m2 day 1 and 2) every 28 days is an effective treatment for relapsed/refractory Hodgkin lymphoma (R/R HL) but associated to high toxicity especially for elderly patients. We conducted in St Louis Hospital, Paris, between 2015 and 2021 a retrospective single-center analysis of 44 patients with R/R HL treated with one-day BV-bendamustine (120 mg/m2) every 21 days. Sixteen percent of patients were ≥ 60 years old (yo). Seventy-three percent of patients received total number of cycles without interruption nor adaptation. No patient ≥ 70 yo required treatment interruption. Dose adjustment was necessary for 18% of patients. Infusion-related reaction (36%) occurred always at cycle 2 and was the only cause of treatment interruption. One febrile neutropenia, one non-documented septic shock, one pyelonephritis on transplanted kidney and one COVID complicated by cytopenias were reported. Sixteen percent patients presented a peripheral sensory neuropathy, 7% and 4% respectively grade 3–4 neutropenia and thrombocytopenia. Overall response was 84%, with 73% of complete remission. Median progression-free survival was of 19.8 months (95% CI 13.1-NR) and median overall survival was not reached with a median follow-up of 31 months. We suggest that one-day BV-bendamustine (120 mg/m2) ever 21 days is a safe and feasible treatment for R/R HL especially for elderly patients.</p>\u0000 </div>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142894048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Idanna Innocenti, Tommaso Quaranta, Annamaria Tomasso, Antonio Mosca, Giulia Benintende, Alberto Fresa, Luigi Maria Larocca, Luca Stirparo, Francesco Iadevaia, Florenzia Vuono, Silvia Bellesi, Arianna Bakacs, Dimitar Efremov, Valter Gattei, Diana Giannarelli, Francesco Autore, Luca Laurenti
{"title":"Implications of Genetic, Biological and Clinical Parameters in Patients With Richter Syndrome: A Monocentric Experience","authors":"Idanna Innocenti, Tommaso Quaranta, Annamaria Tomasso, Antonio Mosca, Giulia Benintende, Alberto Fresa, Luigi Maria Larocca, Luca Stirparo, Francesco Iadevaia, Florenzia Vuono, Silvia Bellesi, Arianna Bakacs, Dimitar Efremov, Valter Gattei, Diana Giannarelli, Francesco Autore, Luca Laurenti","doi":"10.1002/hon.70028","DOIUrl":"10.1002/hon.70028","url":null,"abstract":"","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142894046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Eugenio Galli, Andrea Guarneri, Federica Sorà, Marcello Viscovo, Ilaria Pansini, Elena Maiolo, Eleonora Alma, Salvatore Annunziata, Simona Sica, Lucia Leccisotti, Stefan Hohaus
{"title":"Baseline Tumor Burden Assessed With AI-Guided PET/CT Total Metabolic Tumor Volume (TMTV) and LDH Levels Predict Efficacy of CAR-T in Aggressive B-Cell Lymphoma","authors":"Eugenio Galli, Andrea Guarneri, Federica Sorà, Marcello Viscovo, Ilaria Pansini, Elena Maiolo, Eleonora Alma, Salvatore Annunziata, Simona Sica, Lucia Leccisotti, Stefan Hohaus","doi":"10.1002/hon.70029","DOIUrl":"10.1002/hon.70029","url":null,"abstract":"<p>Disease burden is a critical determinant of outcomes in CAR-T therapy for B-cell lymphomas, and one of the most widely used techniques for its assessment is Total Metabolic Tumor Volume (TMTV) measured via [<sup>18</sup>F]FDG PET/CT. Biological parameters may further refine the risk profile. We analyzed baseline [<sup>18</sup>F]FDG PET/CT scans from 40 patients treated with CAR-T, using an AI-based automated segmentation algorithm to determine TMTV. Our analysis identified that a baseline TMTV greater than 48.4 cm³ and elevated LDH independently predicted progression-free survival (PFS) after CAR-T therapy (HR 4.28, <i>p</i> = 0.007, and HR 8.20, <i>p</i> < 0.001, respectively). We then proposed a 0-to-2 risk score, assigning one point each for elevated TMTV and elevated LDH. All patients with a score of two experienced a PFS of less than 90 days following CAR-T infusion. Among the remaining patients, those with 0 points versus 1 point demonstrated a 3-month PFS of 100% versus 85%, a 6-month PFS of 92% versus 53%, and a 12-month PFS of 83% versus 53%, respectively. Importantly, patients with high baseline TMTV who achieved a TMTV reduction to less than 1.99 cm³ by day 30 had a PFS of 66%, significantly better compared to those who did not achieve this reduction. AI-guided TMTV assessment, combined with LDH levels, provides a rapid and sensitive method for risk stratification at the bedside, which could help optimize patient management prior to CAR-T therapy.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11666922/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142881938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nan Wang, Xin-Yun Huang, Xu-Feng Jiang, Li Wang, Shu Cheng, Peng-Peng Xu, Lei Dong, Bin-Shen Ou-Yang, Rong-Ji Mu, Chen Li, Yan Zhao, Yan Feng, Hong-Jing Dou, Zhong Zheng, Wei-Li Zhao
{"title":"Different Role of PET-CT Evaluation in Newly Diagnosed Follicular Lymphoma Upon Rituximab-Based Chemotherapy and Chemo-Free Immunotherapy","authors":"Nan Wang, Xin-Yun Huang, Xu-Feng Jiang, Li Wang, Shu Cheng, Peng-Peng Xu, Lei Dong, Bin-Shen Ou-Yang, Rong-Ji Mu, Chen Li, Yan Zhao, Yan Feng, Hong-Jing Dou, Zhong Zheng, Wei-Li Zhao","doi":"10.1002/hon.70012","DOIUrl":"10.1002/hon.70012","url":null,"abstract":"<p>Newly diagnosed follicular lymphoma (FL) patients usually received first-line rituximab-based immunochemotherapy (R-chemo). Recently, rituximab plus lenalidomide (R2) emerged as an alternative chemo-free immunotherapy. We performed a comparative analysis of positron emission tomography/computed tomography (PET/CT) in FL undergoing R-chemo or R2. With data of sequential PET/CT at the baseline, interim, and end-of-induction, treatment responses and survival outcomes were analyzed using Deauville scores at the interim and end-of-induction. Additionally, correlations between interim Deauville scores and baseline PET/CT parameters were explored. Conclusively, we revealed that Deauville 1–3 at the interim and end-of-induction showed lower disease progression within 24 months (POD24) and superior progression-free survival (PFS) in R-chemo and R2 cohorts. Also, patients with interim Deauville 1–3 exhibited reduced POD24 and favorable PFS as compared to those with interim Deauville 4–5/end-of-induction Deauville 1–3. Furthermore, total lesion glycolysis of baseline PET-CT surpassed standardized uptake value and total metabolic tumor volume in predicting interim Deauville 1–3, with different optimal cutoffs of 2600 and 600 mL in the R-chemo and R2 cohort. These findings underscored the potential of PET-CT-adapted strategies to achieve durable remission in FL undergoing rituximab-based immunochemotherapy or immunotherapy.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11666925/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142881940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Elena Bibikova, Sara Parsa, Muskan Floren, Brian Law, Tracy Clevenger, Jean Cheung, Gary De Jesus, Kathleen Burke, Michael Gulrajani, Kyoko Yamaguchi, Phuong Do, Brian Dougherty, David Whitston, Graham Brock, Veerendra Munugalavadla, Melanie M. Frigault, Tanja N. Hartmann, John C. Byrd, Richard R. Furman, Jennifer R. Brown, Todd Covey, Andrew Mortlock
{"title":"Molecular Profiling Identifies CD49d and CD79b as Predictive Markers for Acquired Acalabrutinib Resistance in Patients With Chronic Lymphocytic Leukemia","authors":"Elena Bibikova, Sara Parsa, Muskan Floren, Brian Law, Tracy Clevenger, Jean Cheung, Gary De Jesus, Kathleen Burke, Michael Gulrajani, Kyoko Yamaguchi, Phuong Do, Brian Dougherty, David Whitston, Graham Brock, Veerendra Munugalavadla, Melanie M. Frigault, Tanja N. Hartmann, John C. Byrd, Richard R. Furman, Jennifer R. Brown, Todd Covey, Andrew Mortlock","doi":"10.1002/hon.70008","DOIUrl":"10.1002/hon.70008","url":null,"abstract":"<div>\u0000 \u0000 <p>Contemporary studies of Bruton tyrosine kinase inhibitor (BTKi) resistance focus on mutations in the B-cell receptor (BCR) pathway, but alternative mechanisms of resistance remain undefined. Here, we sought to identify novel predictive markers of acquired resistance to acalabrutinib, a second-generation BTKi, in patients with chronic lymphocytic leukemia (CLL). Clinical samples from 41 patients with relapsed/refractory or treatment-naive CLL receiving acalabrutinib as part of a clinical trial (NCT02029443) were divided into two groups: those who continued to respond to treatment (NP, <i>n</i> = 23) and those who developed progressive disease on acalabrutinib therapy (PD, <i>n</i> = 18). Peripheral blood mononuclear cells (PBMCs) from the two groups of patients were profiled at baseline (BL) and at a second timepoint (T2) by RNA-seq and flow cytometry. Our findings show a correlation between acquired resistance to acalabrutinib and upregulation of integrin alpha-4 (<i>ITGA4</i>; CD49d), the BCR surface receptor <i>CD79B</i>, and oncogenes such as <i>MYC</i>, <i>LAG3</i>, and <i>MCL1</i> in CLL cells. High surface expression of CD49d and CD79b prior to acalabrutinib therapy was associated with increased risk of disease progression on acalabrutinib in patients with CLL. When stratified by pretreatment CD49d surface expression, the CD49d<sup>hi</sup> group (defined as ≥ 30% CD49d+ cells at baseline) showed reduced acalabrutinib-induced lymphocytosis and higher levels of tumor proliferation markers such as CD38 and Ki-67 compared with the CD49d<sup>lo</sup> group (defined as < 30% CD49d+ cells at baseline). In summary, CD49d and CD79b are useful predictive markers for CLL progression on acalabrutinib.</p>\u0000 <p><b>Trial Registration:</b> ClinicalTrials.gov identifier: NCT02029443</p>\u0000 </div>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142881942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
